We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-29.17%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$186M
AUM Growth
+$106M
Cap. Flow
+$5.12M
Cap. Flow %
2.76%
Top 10 Hldgs %
78.1%
Holding
120
New
32
Increased
25
Reduced
31
Closed
26

Top Buys

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$5.9M
2
HIND
Vyome Holdings
HIND
+$3.25M
3
CRMD icon
CorMedix
CRMD
+$2.09M
4
TRAW icon
Traws Pharma
TRAW
+$1.84M
5
XBIO icon
Xenetic Biosciences
XBIO
+$1.45M

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.04M
2
SHIPW
Seanergy Maritime Holdings Corp Class A Warrants
SHIPW
+$1.54M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$1.35M
4
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$622K
5
CANF
Can-Fite BioPharma American Depositary Shares
CANF
+$610K

Sector Composition

Rank Sector Weight
1 Healthcare 14.92%
2 Technology 1.81%
3 Industrials 0.77%
4 Consumer Discretionary 0.32%
5 Real Estate 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALBT
51
DELISTED
Avalon GloboCare
ALBT
$369K 0.2%
1,314
-965
-42% -$304K
RNTX
52
Rein Therapeutics
RNTX
$66.9M
$368K 0.2%
27,495
-23,062
-46% -$319K
ORMP icon
53
CALL
Oramed Pharmaceuticals
ORMP
$171M
$357K 0.19%
1,120
+631
+129% +$2.1K
LFWD icon
54
ReWalk Robotics
LFWD
$19.6M
$352K 0.19%
1,369
+437
+47% +$131K
PALI icon
55
Palisade Bio
PALI
$351M
$342K 0.18%
+46
New +$641K
OGEN icon
56
Oragenics
OGEN
$2.24M
$334K 0.18%
344
-356
-51% -$297K
KDMN
57
PUT
DELISTED
Kadmon Holdings, Inc.
KDMN
$321K 0.17%
+114
New +$283
NURO
58
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$299K 0.16%
11,678
+1,559
+15% +$47K
HEPA
59
DELISTED
Hepion Pharmaceuticals
HEPA
$278K 0.15%
+115
New +$334K
XTIA icon
60
XTI Aerospace
XTIA
$57.3M
– –
0
– –
OPTT icon
61
Ocean Power Technologies
OPTT
$40.6M
$269K 0.15%
150,000
+30,688
+26% +$53.6K
XBIOW
62
DELISTED
Xenetic Biosciences, Inc. Warrants
XBIOW
$258K 0.14%
+266,789
New +$499K
IMNN icon
63
Imunon
IMNN
$6.43M
$240K 0.13%
798
+640
+405% +$219K
CYTR
64
DELISTED
CytRx Corp
CYTR
$237K 0.13%
729,450
-331,549
-31% -$108K
RKDA icon
65
Arcadia Biosciences
RKDA
$1.37M
$234K 0.13%
1,251
+750
+150% +$144K
BLIN icon
66
Bridgeline Digital
BLIN
$14.9M
$210K 0.11%
110,000
-400
-0.4% -$851
ABIL
67
DELISTED
Ability Inc
ABIL
$178K 0.1%
312,642
+11,505
+4% +$8.24K
CVM.WS
68
CALL
DELISTED
Cel-Sci Corp Series S
CVM.WS
$167K 0.09%
187
+87
+87% +$77.7K
NTBL
69
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$162K 0.09%
3,419
-3,415
-50% -$151K
AIM
70
AIM ImmunoTech
AIM
$6.54M
$141K 0.08%
1,854
+1,245
+204% +$301K
PLUR icon
71
Pluri
PLUR
$18.1M
$139K 0.07%
+4,649
New +$171K
VKTX icon
72
CALL
Viking Therapeutics
VKTX
$3.93B
$138K 0.07%
200
– –
SHIPZ
73
DELISTED
Seanergy Maritime Holdings Corp Class B Warrant
SHIPZ
$138K 0.07%
917,337
+28,448
+3% +$5.26K
DMK
74
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$129K 0.07%
+2,619
New +$188K
MDGSW
75
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$101K 0.05%
1,008,444
-22,210
-2% -$10.7K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sabby Management held 120 positions worth $186M, up 133% from $79.5M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Sabby Management's Q3 2019 filing shows 32 new, 25 increased, 31 reduced and 26 closed positions. Its largest new stake was Pareteum Corporation: 2,248,578 shares worth $2.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 37% a quarter earlier, followed by Technology and Industrials.

  • Sabby Management's largest Q3 2019 buy was Pareteum Corporation: 2,248,578 shares worth $2.9M.
  • Sabby Management added most to Advaxis Inc in Q3 2019, an estimated $1.01M increase.
  • Sabby Management's biggest Q3 2019 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $1.35M.
  • Sabby Management fully exited Ampio Pharmaceuticals Inc. in Q3 2019, selling an estimated $2.04M.
  • Sabby Management's ten largest holdings make up 78% of its $186M portfolio in Q3 2019.
  • Sabby Management opened 32 new positions and closed 26 in Q3 2019.
  • Sabby Management's portfolio value rose 133% quarter-over-quarter to $186M.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.